Should you be interested in the study participation, please, contact us at: rberkovich.research@gmail.com

Current Enrolling Studies

FREXALT (Open to Enrollment):

Phase 3 Study of Frexalimab in Relapsing Multiple Sclerosis

Protocol # EFC 17919

Site: 8400005

Sponsor: Sanofi

ClinicalTrials.gov Identifier: NCT06141473

Link

FREVIVA (Open to Enrollment):

Phase 3 Study of Frexalimab in Progressive Multiple Sclerosis

Protocol # EFC 17504

Site: 8400005

Sponsor: Sanofi

ClinicalTrials.gov Identifier: NCT06141486

Link

REMODEL (Open to Enrollment):

Phase 3 Study of Remibrutinib in Relapsing Multiple Sclerosis

Protocol # CLOU064C12302

Site: 5064

Sponsor: Novartis

ClinicalTrials.gov Identifier: NCT05156281

Link

Ongoing Studies (enrollment closed)

EVOLUTION

Phase 3 Study of Evobrutinib in Relapsing Multiple Sclerosis

Protocol # MS200527_0082

Site: 737

Sponsor: EMD Serono Research & Development Institute, Inc.

ClinicalTrials.gov Identifier: NCT04338061

Link

HERCULES

Phase 3 Study of Tolebrutinib in Relapsing Multiple Sclerosis

Protocol # EFC16645

Site: 8400059

Sponsor: Sanofi

ClinicalTrials.gov Identifier: NCT04411641

Link

AGNOS

Phase 4 Study of Ofatumumab in Relapsing Multiple Sclerosis

Protocol # COMB157GUS10

Site: 1003

Sponsor: Novartis

ClinicalTrials.gov Identifier: NCT05084638

Link

MASTER-2

Phase 4 Study of Cladribine in Relapsing Multiple Sclerosis

Protocol # MS700568_0079

Site: 954

Sponsor: EMD Serono, Inc.

ClinicalTrials.gov Identifier: NCT03933202

Link